5/2/2023 9:04:10 AM
CSL Vifor Says DUPLEX Study Did Not Achieve Primary Efficacy EGFR Slope Endpoint Over 108 Weeks Of Treatment
3/28/2023 1:06:16 AM
Vifor Fresenius Medical Care Renal Pharma Says Tavneos Included In Revised EULAR AAV Management Recommendations
12/12/2022 8:38:06 AM
CSL Seqirus Finalizes Global Collaboration And License Agreement With Arcturus Therapeutics Holdings
9/26/2022 8:05:07 AM
CSL Says Data Shows Cell-Based And MF59-Adjuvanted Influenza Vaccines Reduce Burden Of Seasonal Influenza On Hospitals
7/13/2022 1:09:13 AM
CSL Announces Postponement Of Settlement Of Vifor Pharma Tender Offer Until September 30, 2022
12/14/2021 12:50:39 AM
CSL To Acquire Vifor Pharma For Aggregate Equity Value For Vifor Pharma Of $11.7/CHF 10.9 Bln